{
      "Rank": 2,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .\n\nMSC a day-case 2\u00b70\u00d7106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v.",
            "Patients with progressive and refractory NMO treated with regular methods"
      ],
      "ArmGroupInterventionName": [
            "Biological: Autologous mesenchymal stem cells",
            "Biological: Autologous mesenchymal stem cells"
      ],
      "ArmGroupLabel": [
            "Autologous mesenchymal stem cells group",
            "Control group"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02249676"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Neuromyelitis optica (NMO) is a demyelinating and degenerative disorder of the central nervous system affecting vision and brain and spinal cord function which leads to accumulating disability with a 5 year-mortality of approximately 30%. Survivors are typically left with severe morbidity secondary to blindness, quadriparesis and respiratory failure. No agent has been found to be highly effective in halting disease activity.Based on recent outcomes of Multipotent mesenchymal stromal cells in autoimmune diseases including multiple sclerosis, and based on the mechanisms of neuromyelitis optica, the investigators anticipate that mesenchymal stem cells transplantation may provide lasting disease stability for neuromyelitis optica patients."
      ],
      "BriefTitle": [
            "Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 31, 2014"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Devic's Syndrome",
            "Devic's Neuromyelitis Optica",
            "Devic Syndrome",
            "Devic's Disease",
            "Devic Disease"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000009188",
            "D000020278",
            "D000020274",
            "D000009422",
            "D000009902",
            "D000009901",
            "D000003389",
            "D000003711",
            "D000005128",
            "D000001327",
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Myelitis, Transverse",
            "Demyelinating Autoimmune Diseases, CNS",
            "Autoimmune Diseases of the Nervous System",
            "Nervous System Diseases",
            "Optic Neuritis",
            "Optic Nerve Diseases",
            "Cranial Nerve Diseases",
            "Demyelinating Diseases",
            "Eye Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC10",
            "BC11",
            "BC20",
            "BC01",
            "BC04",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Nervous System Diseases",
            "Eye Diseases",
            "Immune System Diseases",
            "Infections",
            "Neoplasms",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Syndrome",
            "Neuromyelitis Optica",
            "Neuromyelitis Optica"
      ],
      "ConditionBrowseLeafId": [
            "M15507",
            "M11566",
            "M11294",
            "M11295",
            "M3781",
            "M21251",
            "M21247",
            "M11539",
            "M11985",
            "M11984",
            "M5757",
            "M6061",
            "M7423",
            "M9352",
            "T4103",
            "T3988",
            "T4263"
      ],
      "ConditionBrowseLeafName": [
            "Syndrome",
            "Neuromyelitis Optica",
            "Myelitis",
            "Myelitis, Transverse",
            "Autoimmune Diseases",
            "Demyelinating Autoimmune Diseases, CNS",
            "Autoimmune Diseases of the Nervous System",
            "Neuritis",
            "Optic Neuritis",
            "Optic Nerve Diseases",
            "Cranial Nerve Diseases",
            "Demyelinating Diseases",
            "Eye Diseases",
            "Immune System Diseases",
            "Neuromyelitis Optica Spectrum Disorder",
            "Myelitis",
            "Optic Neuritis"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000009471",
            "D000013577"
      ],
      "ConditionMeshTerm": [
            "Neuromyelitis Optica",
            "Syndrome"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Primary objective was to assess feasibility and safety; the investigators compared adverse events from up to 3months before treatment until up to 12 months after the infusion.\n\nAs a secondary objective, the investigators chose efficacy outcomes to assess the Expanded Disability Status (EDSS)\u3001annual relapse rate (ARR) and time to next relapse after transplant.\n\nThird objective anterior visual pathway and pyramidal tract as a model of wider disease. Masked endpoint analyses was used for electrophysiological and selected imaging outcomes."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nClinically definite neuromyelitis optica or neuromyelitis optica spectrum disorder\nAge > 18 year\nEDSS > 3\n\nProgression continued relapses or worsening MRI after at least a year of attempted therapy as evidenced by one or more of the following:\n\nIncrease of 1 EDSS point (if baseline EDSS<5.0) or 0.5 EDSS points (if baseline EDSS >5.5)\nModerate-severe relapses in past 18 months\nGadolinium enhancing lesions (double or triple dose Gd)\n1 new T2 lesion\n\nEvidence of recent inflammatory disease, as evidenced by any one of the following:\n\n1 moderate-severe relapses in past 18 months\n1 Gd-enhancing lesions (single, double or triple dose Gd)\n1 new T2 lesion\n\nExclusion Criteria:\n\nReceived Immune inhibitors immunomodulator during the three months before the trial\nSignificant cardiac, renal, or hepatic failure or any other disease that may affect the results of the study\nAllergies\nPregnant or possibly pregnant\nCognitive decline to understand or sign the informed consent\nBrain tumor, HIV (+) tumor marker (+), blood pressure (BP): 200 /110 mmHg\nJudged not suitable by doctors"
      ],
      "EnrollmentCount": [
            "15"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Autologous mesenchymal stem cells group",
            "Control group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "AnEm",
            "Gast",
            "All",
            "Infl",
            "AAll",
            "Derm"
      ],
      "InterventionBrowseBranchName": [
            "Antiemetics",
            "Gastrointestinal Agents",
            "All Drugs and Chemicals",
            "Anti-Inflammatory Agents",
            "Anti-Allergic Agents",
            "Dermatologic Agents"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M10912",
            "M9064",
            "M155022",
            "M228602",
            "M263157",
            "M5137"
      ],
      "InterventionBrowseLeafName": [
            "Metoclopramide",
            "Hydrocortisone",
            "Hydrocortisone 17-butyrate 21-propionate",
            "Hydrocortisone acetate",
            "Hydrocortisone hemisuccinate",
            "Chlorpheniramine"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Autologous mesenchymal stem cells"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Autologous mesenchymal stem cells"
      ],
      "InterventionOtherName": [
            "MSC"
      ],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Autologous mesenchymal stem cells",
            "neuromyelitis optica",
            "treatment"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "October 17, 2018"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "October 15, 2018"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Tianjin Medical University General Hospital"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Tianjin"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "Tianjin Medical University General Hospital"
      ],
      "LocationState": [
            "Tianjin"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "300052"
      ],
      "MaximumAge": [
            "80 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Autologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept Study"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Tianjin Medical University General Hospital"
      ],
      "OrgStudyId": [
            "IRB2013-055-02"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Tianjin Medical University General Hospital"
      ],
      "OverallOfficialName": [
            "Fu-Dong Shi, MD,PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 31, 2014"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Compare EDSS change before and one year after mesenchymal stem cells (MSC) infusion"
      ],
      "PrimaryOutcomeMeasure": [
            "EDSS"
      ],
      "PrimaryOutcomeTimeFrame": [
            "change from baseline to one year"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Tianjin Medical University General Hospital"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Fu-Dong Shi"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Head of Neurology Department"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Compare annual relapse rate before and one year after MSC infusion",
            "Compared lesion load before and one year after MSC infusion",
            "Compared RNFL before and one year after MSC infusion",
            "Compare cognition questionnaire scale before and one year after MSC infusion",
            "Compare anti-aquaporin4-ab before and one year after MSC infusion.",
            "Compare immune cell subpopulation before and one year after MSC infusion.",
            "Compare cytokine kinetics before and one year after MSC infusion.",
            "Compare cerebral volume before and one year after MSC infusion"
      ],
      "SecondaryOutcomeMeasure": [
            "Annual relapse rate",
            "Lesion load",
            "Retinal nerve fiber layer (RNFL)",
            "Cognition",
            "Immunological assessments",
            "Immunological assessments",
            "Immunological assessments",
            "cerebral volume"
      ],
      "SecondaryOutcomeTimeFrame": [
            "1 year after infusion",
            "1 year after infusion",
            "1 year after infusion",
            "1 year after infusion",
            "1 year after infusion",
            "1 year after infusion",
            "1 year after infusion",
            "1 year after infusion"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "January 2013"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "October 2018"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "September 25, 2014"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "September 15, 2014"
      ],
      "StudyFirstSubmitQCDate": [
            "September 22, 2014"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}